Clinical TrialID 5645

Treatment of Patients With Periorbital Hyperpigmentation

NCT04389788

Periorbital Hypermelanosis

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5645
Evidence Id
5645
Core Evidence Id
5645
Source Clinical Trial Id
5630
Herb2 Clinical Trial Id
HBCT005630
Nct Id
NCT04389788
Title
Treatment of Patients With Periorbital Hyperpigmentation
Status
Completed
Phase
Study Result
No
Study Condition
Periorbital Hypermelanosis
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Intervention
DEVICE: carboxy therapy|DEVICE: Dermapen with topical glutathione
Intervention Allocation
Non_Randomized
Intervention Model
Single_Group
Intervention Mask
Double
Intervention Purpose
Treatment
Gender
Female
Age
Adult, Older_Adult
Enrollment
31
Outcome Measure
Change of periorbital hyperpigmentation through photo evaluation, High-resolution photographs of both sides of the face were taken. Using a physician visual analog scoring system, 2 independent blinded dermatologists will rate the patient's overall aesthetic improvement as follows 1 (worse), 2 (no change), 3 (\<30%), 4 (30-60%), and 5 (\>60%), Baseline, before 3rd session, before 5th session, 1 month after end of treatment, 2 months after end of treatment|Change of periorbital hyperpigmentation through dermoscopy evaluation, Dermoscopic evaluation was done using dermalite connection kit for Samsung galaxy. 2 independent blinded dermatologists will rate the patient's overall aesthetic improvement as follows * Vasculature improvement (No 0, Yes 1) \& percent of improvement. * Pigmentation improvement (No 0, Yes 1) \& percent of improvement. * Skin improvement like atrophy and exaggerated skin markings (No 0, Yes 1) \& percent of improvement., Baseline, before 3rd session, before 5th session, 1 month after end of treatment, 2 months after end of treatment|Change of the patient satisfaction evaluation: scale, The patients were asked to evaluate their own level of satisfaction after they completed the study on a 1-3 scale: 1 = slightly satisfied, 2 = moderately satisfied, and 3 = well satisfied, Baseline and 1 month after end of treatment|Change of periorbital hyperpigmentation into another skin problem through safety evaluation, Safety evaluation to detect precentage of side effects reported either by the patient or by the physician., Baseline, before 3rd session, before 5th session, 1 month after end of treatment, 2 months after end of treatment
Sponsor Collaborator
Sohag University
Funded By
OTHER
Location
Faculty of Medicine, Sohag University, Sohag, 82524, Egypt
Other Id
Sohagu309
Start Date
2020-02-12
Primary Completion Date
2020-10-10
Completion Date
2020-10-21
First Posted
2020-05-15
Results First Posted
Last Update Posted
2020-10-23
Study Document
Study Url
https://clinicaltrials.gov/study/NCT04389788
Title Cn
Title En
Treatment of Patients With Periorbital Hyperpigmentation
Bilingual Status
semi_complete